Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Patrikidou, Anna ^a   Vlachostergios, Panagiotis J ^b   Voutsadakis, Ioannis A ^c   Hatzidaki, Eleana ^b   Valeri, Rosalia Maria ^d   Destouni, Chariklia ^d   Apostolou, Effie ^e,f   Papandreou, Christos N ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d THEAGENIO CANCER HOSPITAL   (Greece)

^e BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEASOME; PROTEASOME INHIBITOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84862320545     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-31     Document Type: Article

References (52)

1. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004, 64:5036-5043. 10.1158/0008-5472.CAN-03-2707, 15289299.
2. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Kaur P, Gray K, Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004, 10:2466-2472. 10.1158/1078-0432.CCR-0543-3, 15073126.
3. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?. World J Urol 2007, 25:477-489. 10.1007/s00345-007-0175-6, 17541600.
4. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000, 42:186-195. 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E, 10639189.
5. Sanford DC, Dewille JW. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate 2005, 63:143-154. 10.1002/pros.20159, 15486993.
6. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008, 68:6762-6729. 10.1158/0008-5472.CAN-08-0107, 2840631, 18701501.
7. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005, 7:759-763.
8. DeMartino GN, Gillette TG. Proteasomes: machines for all reasons. Cell 2007, 129:659-662. 10.1016/j.cell.2007.05.007, 17512401.
9. Vlachostergios PJ, Patrikidou A, Daliani DD, Papandreou CN. The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation. J Cell Mol Med 2009, 13:3006-3018. 10.1111/j.1582-4934.2009.00824.x, 19522845.
10. Vlachostergios PJ, Patrikidou A, Daliani DD, Papandreou CN. The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. J Cell Mol Med 2009, 13:3019-3031. 10.1111/j.1582-4934.2009.00825.x, 19522844.
11. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Steins H, Sundays ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991, 88:10662-10666. 10.1073/pnas.88.23.10662, 52990, 1660144.
12. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!. Blood 1993, 84:1052-1070.
13. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. BioEssays 2001, 23:261-269. 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K, 11223883.
14. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Investig 1993, 91:1969-1973. 10.1172/JCI116417, 288193, 8486767.
15. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989, 63:1714-1720.
16. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberg MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1:944-949. 10.1038/nm0995-944, 7585222.
17. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996, 56:663-668.
18. Godara G, Pecher S, Jukic DM, D' Antonio JM, Akhavan A, Nelson JB, Pflug BR. Distinct patterns of endothelin axis expression in primary prostate cancer. Urology 2007, 70:209-215.
19. Aprikian AG, Tremblay L, Han K, Chevalier S. Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins. Int J Cancer 1997, 72:498-504. 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.0.CO;2-8, 9247295.
20. Festuccia C, Guerra F, D'Ascenzo S, Giunciuglio D, Albini A, Bologna M. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer 1998, 75:418-431. 10.1002/(SICI)1097-0215(19980130)75:3<418::AID-IJC16>3.0.CO;2-4, 9455804.
21. Dai J, Shen R, Sumitomo M, Goldberg JS, Geng Y, Navarro D, Xu S, Koutcher JA, Garzotto M, Powell CT, Nanus DM. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res 2001, 7:1370-1377.
22. Sumitomo M, Milowsky MI, Shen R, Navarro D, Dai J, Asano T, Hayakawa M, Nanus DM. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001, 61:3294-3298.
23. Levine L, Lucci JA, Pazdrak B, Cheng JZ, Guo YS, Townsend CM, Hellmich MR. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003, 63:3495-3502.
24. Dawson LA, Maitland NJ, Turner AJ, Usmani BA. Stromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expression. Br J Cancer 2006, 90:1577-1582.
25. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993, 14:385-389. 10.1016/0196-9781(93)90057-N, 8483816.
26. Steiner MS. Role of peptide growth factors in prostate. Urology 1993, 42:88-110.
27. Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate:ancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994, 25:29-38. 10.1002/pros.2990250105, 8022709.
28. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J Mol Endocrinol 1996, 16:297-306. 10.1677/jme.0.0160297, 8782088.
29. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
30. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human PCs. Prostate 2000, 42:295-303. 10.1002/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B, 10679759.
31. Papandreou CN, Usmani BA, Geng Y, Bogenreider T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998, 4:50-57. 10.1038/nm0198-050, 9427606.
32. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, Nelson JB, Nanus DM. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000, 6:1664-1670.
33. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinol 2000, 141:1699-1704.
34. Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol 2000, 170:131-142. 10.1016/S0303-7207(00)00326-9, 11162897.
35. Nanus DM. Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res 2003, 9:6307-6309.
36. Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H. An essential role for nuclear factor kappa B in preventing TNF-α-induced cell death in prostate cancer cells. J Urol 1999, 161:674-679. 10.1016/S0022-5347(01)61993-1, 9915481.
37. Muenchen HJ, Lin DL, Walsh MA, Keller ET, Pienta KJ. Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha " super-repressor" . Clin Cancer Res 2000, 6:1969-1977.
38. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2001, 18:471-479.
39. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002, 115:141-151.
40. Patrikidou A, Vlachostergios PJ, Voutsadakis IA, Hatzidaki E, Valeri RM, Destouni C, Apostolou E, Daliani D, Papandreou CN. Inverse baseline expression pattern of the NEP/neuropeptides and NFkappaB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int 2011, 11:13. 10.1186/1475-2867-11-13, 3121665, 21569620.
41. Carter AB, Monick MM, Hunninghake GW. Lipopolysaccharide-induced NF-kappaB activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PC-PLC-dependent. Am J Respir Cell Mol Biol 1998, 18:384-391.
42. Ouadrhiri Y, Pilette C, Monteiro RC, Vaerman JP, Sibille Y. Effect of IgA on respiratory burst and cytokine release by human alveolar macrophages: role of ERK1/2 mitogen-activated protein kinases and NF-kappaB. Am J Respir Cell Mol Biol 2002, 26:315-332.
43. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004, 11:36-42.
44. Thanos D, Maniatis T. Identification of the rel family members required for family inductions of the human beta interferon gene. Mol Cell Biol 1995, 15:152-164. 231925, 7799921.
45. Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. Int J Urol 2012, Epub ahead of print.
46. de Visser M, Bernard HF, Erion JL, Schmidt MA, Srinivasan A, Waser B, Reubi JC, Krenning EP, de Jung M. Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur J Nucl Med Mol Imaging 2007, 34:1228-1238. 10.1007/s00259-006-0356-3, 17287960.
47. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 2005, 65:130-140. 10.1002/pros.20234, 15880609.
48. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res 2005, 65:9891-9898. 10.1158/0008-5472.CAN-05-1293, 16267013.
49. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gélinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002, 52:183-200. 10.1002/pros.10082, 12111695.
50. Browatzki M, Schmidt J, Kübler W, Kranzhöfer R. Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2002, 95:98-105.
51. Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D, Cher M, Sarkar FH. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007, 67:3818-3826. 10.1158/0008-5472.CAN-06-3879, 17440096.
52. Usmani B, Harden B, Maitland NJ, Turner AJ. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci 2002, 103:3145-3175.